Cargando…

Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder

BACKGROUND: Neurofilament light chain (NfL) and glial fibrilliary acidic protein (GFAP) have been suggested to be biomarkers of the pathophysiological process of neuromyelitis optica spectrum disorders (NMOSD), but the relationship between the plasma levels of these molecules with disease activity a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Tian-Xiang, Chen, Jing-Shan, Du, Chen, Zeng, Pei, Zhang, Huiming, Wang, Xuejiao, Liu, Ye, Huang, Zhenning, Yuan, Meng, Li, Yu-Lin, Jia, Dongmei, Shi, Fu-Dong, Zhang, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573482/ https://www.ncbi.nlm.nih.gov/pubmed/34777577 http://dx.doi.org/10.1177/17562864211054952

Ejemplares similares

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
por: Aktas, Orhan, et al.
Publicado: (2021)

Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders
por: Kim, Hyunjin, et al.
Publicado: (2022)

The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
por: Storoni, Mithu, et al.
Publicado: (2011)

Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL
por: Chen, Chih-Hao, et al.
Publicado: (2020)

Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy
por: Beerepoot, Shanice, et al.
Publicado: (2021)

Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
por: Hyun, Jae-Won, et al.
Publicado: (2021)

Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria
por: Lotz-Havla, Amelie S., et al.
Publicado: (2022)

Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease
por: Parvizi, Tandis, et al.
Publicado: (2022)

Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder
por: Liu, Ye, et al.
Publicado: (2021)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study
por: Simone, Marta, et al.
Publicado: (2023)

Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases
por: Kim, Su-Hyun, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia
por: Rodrigues-Amorim, Daniela, et al.
Publicado: (2020)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury
por: Laverse, Etienne, et al.
Publicado: (2020)

Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder
por: Zeng, Pei, et al.
Publicado: (2021)

Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke
por: Barba, Lorenzo, et al.
Publicado: (2023)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4
por: Kessler, Christoph, et al.
Publicado: (2022)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder
por: Du, Chen, et al.
Publicado: (2021)

Neuromyelitis optica spectrum disorders: An update
por: Pandit, Lekha
Publicado: (2015)

Treatment of Neuromyelitis Optica Spectrum Disorders
por: Chan, Koon-Ho, et al.
Publicado: (2021)

Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction
por: Vågberg, Mattias, et al.
Publicado: (2015)

Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas
por: Hepner, Adriana, et al.
Publicado: (2019)

Association of CSF and Serum Neurofilament Light and Glial Fibrillary Acidic Protein, Injury Severity, and Outcome in Spinal Cord Injury
por: Stukas, Sophie, et al.
Publicado: (2023)

Extracellular vesicle concentrations of glial fibrillary acidic protein and neurofilament light measured 1 year after traumatic brain injury
por: Flynn, Spencer, et al.
Publicado: (2021)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
por: Fan, Xueli, et al.
Publicado: (2016)

Neuromyelitis optica spectrum disorders without and with autoimmune diseases
por: Zhang, Bingjun, et al.
Publicado: (2014)

Muscle damage in patients with neuromyelitis optica spectrum disorder
por: Chen, Hong-xi, et al.
Publicado: (2017)

Mortality of neuromyelitis optica spectrum disorders in a Chinese population
por: Du, Qin, et al.
Publicado: (2021)

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
por: Fan, Moli, et al.
Publicado: (2020)

Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
por: Jagtap, Sujit Abajirao, et al.
Publicado: (2015)

Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder
por: Eskandarieh, Sharareh, et al.
Publicado: (2019)

Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
por: Kim, Woojun, et al.
Publicado: (2012)

Sleep abnormality in neuromyelitis optica spectrum disorder
por: Song, Yijun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7q1419667tlbhqtkmf62u397b9